Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 4/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | PHLPP1 | O60346 | 2/20 | 0.36 |
| ▸ | ILK | Q13418 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860037 | 0.83 | PPARG (0.45) | PPARGPPARAAKT1NR1I2 | |
| SCHEMBL5859969 | 0.78 | L3MBTL1 (0.44) | PPARGPPARAAKT1ALOX5NR1I2 | |
| SCHEMBL7795202 | 0.74 | MEN1 (0.37) | ALOX5NR1I2 | |
| SCHEMBL5859190 | 0.72 | AKT1 (0.42) | PPARGPPARAAKT1ALOX5NR1I2 | |
| SCHEMBL5859975 | 0.70 | PPARG (0.46) | PPARGPPARALMNA | |
| SCHEMBL24157975 | 0.70 | KMT2A (0.48) | — | |
| SCHEMBL5859204 | 0.69 | PPARG (0.45) | PPARGPPARAAKT1 | |
| SCHEMBL9816262 | 0.67 | PTGS1 (0.54) | ALOX5NR1I2LMNA | |
| SCHEMBL6499643 | 0.65 | GAA (0.50) | — | |
| SCHEMBL7330589 | 0.64 | MEN1 (0.58) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109222-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-19 | — | — | US | disclosed |
| US-6867224-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885AKT1 735/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885AKT1 735/4885 |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885AKT1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.